A Phase 2, Open-label, Multicenter Study to Explore the Efficacy and Safety of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Mongersen (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 06 Sep 2017 This trial was completed in Bulgarian (on-2017-08-08), according to European Clinical Trials Database.
- 31 Aug 2017 Status changed from active, no longer recruiting to completed.
- 27 Jul 2017 According to a celgene corporation media release, data from this trial is expected in second half of 2017.